Eris Lifesciences to host Q1 FY27 earnings call on July 29

Eris Lifesciences Limited will hold a conference call for analysts and investors on July 29, 2026, at 4:30 PM IST to discuss the unaudited financial results for the quarter ended June 30, 2026. The meeting is scheduled pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, following the Board of Directors' meeting to consider and approve the standalone and consolidated financial results for Q1 FY2027.

The conference call provides a platform for the company to present its quarterly performance and outlook. Investors and analysts interested in participating must pre-register through Zoom using the provided link. The details of the call are also available on the company's official website.

Q1 FY2027 Earnings Call Details

Parameter	Details
Date	Wednesday, July 29, 2026
Time	4:30 PM IST
Access	Zoom (Pre-registration required)
Registration Link	Zoom Webinar

Milind Talegaonkar, Company Secretary and Compliance Officer, signed the intimation regarding the schedule on July 23, 2026. The company's registered office is located in Ahmedabad, Gujarat.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.12%	-4.39%	-2.85%	-1.63%	-21.41%	+83.41%

Eris Lifesciences has laid out a set of strategic financial targets for FY27, signaling confidence in its growth trajectory. The company is aiming for an 18-20% increase in revenue during the fiscal year, while maintaining steady EBITDA margins — a combination that reflects its focus on both top-line expansion and operational efficiency.

Key FY27 Financial and Operational Targets

The company's FY27 roadmap encompasses revenue growth, margin stability, and a specific outperformance benchmark relative to its CVM. The following table summarizes the key targets announced:

Parameter:	Details
Revenue Growth Target:	18-20%
EBITDA Margin Outlook:	Steady
Growth vs. CVM:	1.3 times CVM
Sundae Pens In-Sourcing Start:	Q2 FY27

Sundae Pens In-Sourcing as a Growth Catalyst

A notable operational development underpinning Eris Lifesciences' FY27 outlook is the planned in-sourcing of Sundae Pens, scheduled to begin from Q2 FY27. This move is expected to contribute meaningfully to the company's ability to achieve growth at 1.3 times the CVM, positioning in-sourcing as a strategic lever for both cost management and supply chain control.

Growth Benchmarked Against CVM

Eris Lifesciences has set a target to grow at 1.3 times the CVM, indicating an ambition to outpace the broader chronic and vaccine market segment. This benchmark, combined with the 18-20% revenue growth target and steady EBITDA margins, reflects the company's multi-pronged approach to FY27 performance.